DiaCarta

Pleasanton, United States· Est. 2013

DiaCarta Redefines Precision Molecular Diagnostics through Cancer Gene Mutation Detection Test.

Private Company

Total funding raised: $115M

About

DiaCarta Redefines Precision Molecular Diagnostics through Cancer Gene Mutation Detection Test.

Diagnostics

Funding History

2

Total raised:$115M

Series C$70MEfung CapitalFeb 15, 2021

Series B$45MEfung CapitalJun 15, 2018

More companies in Diagnostics & Precision Medicine →More companies in United States →